Expression of SART3 tumor-rejection antigen in gastric cancers

Fumihiko Niiya, Shinya Nishizaka, Kazuko Matsunaga, Kikuo Koufuji, Masaki Mori, Hitoshi Katai, Hideaki Yamana, Kyogo Itoh

研究成果: ジャーナルへの寄稿学術誌査読

17 被引用数 (Scopus)

抄録

We previously reported SART3 as a tumor-rejection antigen recognized by histocompatibility leukocyte antigen (HLA)-A24-restricted cytotoxic T lymphocytes (CTLs). In this study, we investigated the expression of the SART3 antigen in gastric cancers, as a candidate for use in specific immunotherapy. The SART3 antigen was detected in 9 of 10 (90%) gastric cancer cell lines, 35 of 52 (67.3%) gastric cancer tissues, and 0 of 20 non-tumorous gastric tissues. SART3-derived peptides corresponding to positions 109-118 and 315-323 induced HLA-A24-restricted and tumor-specific CTLs from peripheral blood mononuclear cells (PBMCs) of gastric cancer patients. These peptide-induced CTLs recognized HLA-A24+ SART3+ gastric cancer cells, but not HLA-A24+ SART3- or HLA-A24- SART3+ gastric cancer cells. Therefore, the SART3 peptides could be useful in specific immunotherapy of gastric cancer patients.

本文言語英語
ページ(範囲)337-342
ページ数6
ジャーナルJapanese Journal of Cancer Research
91
3
DOI
出版ステータス出版済み - 3月 2000

!!!All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究

フィンガープリント

「Expression of SART3 tumor-rejection antigen in gastric cancers」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル